Data availability
Data is transparent.
Code availability
N/A.
References
Niinimaki R, Aarnivala H, Banerjee J, Pokka T, Vepsalainen K and Harila-Saari A (2010) Reduced dose folinic acid rescue after high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort. Support Care Cancer https://doi.org/10.1007/s00520-021-06395-3
Joseph Cohen Ian, Johannes Wolff (2014) How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatric Blood and Cancer 61:7–10
Borsi JD, Moe PJ (1987) A comparative study on the pharmacokinetics of methotrexate in the dose range of 0.5g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 60:5–13
Millot F, Rubie H, Mazingue F, Mechinaud F, Thyss (1994) Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5g/m2 metotrexate. Leuk Lymphoma 14:141–144
Cohen IJ (2017) Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue. Cancer Chemother Pharmacol 79:1057–1065
Cohen IJ (2021) Folinic acid over rescue of high dose methotrexate: how problematic citations conserve discredited concepts. Medical Hypotheses https://doi.org/10.1016/J.mehy.2020.110467
Borsi DJ, Wesenberg F, Stockland T, Moe PJ (1991) How much is too much? Folinic acid rescue in children with acute lymphatic leukemia. Eu J Cancer 27:1006–1009
Skarby TV, Anderson H, Heldrup J et al (2006) High leukoverin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphatic leukemia. Leukemia 20:1955–1962
Montour-Proulx I, Kuehn SM, Keene DL et al (2005) Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the pediatric oncology group 9605 protocol. J Child Neurol 20:129–133
Bell B, Abish S, Shuster J, Camitta B (1997) Neurotoxicity (NT) in patients with standard – risk acute lymphoblastic leukemia on pediatric oncology group protocol (POG) 9405. Blood 90:559A
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
N/A.
Consent to participate
N/A.
Consent for publication
N/A.
Conflict of interest
The author declares no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cohen, I.J. Lack of neurotoxicity after rapid clearance of high dose methotrexate followed by minimal dose folinic acid. Support Care Cancer 30, 1899–1900 (2022). https://doi.org/10.1007/s00520-021-06464-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-021-06464-7